Conference Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 443 - SPEED: Statistical Methods and Applications in Medical Research, Risk Analysis, and Marketing Part 2
Type: Contributed
Date/Time: Wednesday, August 10, 2022 : 10:30 AM to 11:15 AM
Sponsor: Biopharmaceutical Section
Abstract #323827
Title: Dose Finding via Efficacy Biomarkers and Toxicity Endpoints in Immuno-Oncology Clinical Trials
Author(s): Yiding Zhang* and Zhixing Xu and Ji Lin and Hui Quan
Companies: Sanofi and Sanofi and Sanofi and Sanofi
Keywords: Bayesian adaptive design; dose finding; Immunotherapy; biomarker; phase I-II trial; optimal dose

The primary objective of phase I oncology studies is to establish the safety profile of a new treatment and determine the maximum tolerated dose (MTD). This is motivated by the development of cytotoxic agents based on the underlying assumption that the higher the dose, the greater the likelihood of efficacy and toxicity. However, evidence from the recent development of cancer immunotherapies that aim to stimulate patients’ immune systems to fight cancer challenges this assumption, particularly further escalation after certain dose level might not necessarily increase the efficacy. Dose escalation study of molecular targeted agents (MTA) often does not only rely on the safety profile. In this paper, we propose a simple and flexible model that uses multivariate Gaussian latent variable to integrate toxicity endpoint and efficacy biomarker. This model can be easily extended to incorporate additional immune biomarkers. By simultaneously considering multiple outcomes, the proposed method is better to identify the biologically optimal dose, which results in better decision-making. Simulation studies showed that the proposed method has desirable operating characteristics by determining the target dose with an optimal risk-benefit trade-off. We have also implemented our proposed method in a user-friendly R Shiny tool.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2022 program